On Tuesday, a Swiss manufacturer of hearing aids, Sonova (SOON.S), lowered its projection for the entire year’s core earnings, citing more significant investments as the reason. These investments are intended to maintain the positive trajectory in the company’s Hearing Instruments and Audiological Care divisions.
Compared to an earlier target range of 6% to 10%, the largest manufacturer of hearing aids in the world anticipates that its annual adjusted earnings before interest, taxes, and amortization (EBITA) will grow between 4% and 8% at constant currency rates.
Even though the market has recovered from the COVID-related lockdowns that prohibited individuals from seeing doctors or audiologists, demand has remained subdued since inflation has persisted at a stubbornly high level.
Sonova’s sales in the United States, the company’s second-largest market, decreased by 4.6% in local currency due to the failure of a substantial contract with a client that shall remain nameless to be extended.
For the first six months of its fiscal year, Sonova reported an adjusted EBITA of 350 million Swiss francs ($395.26 million), representing an increase of 2.5% in local currencies but a decrease of 12.1% in Swiss francs. This figure came in significantly lower than the average estimate of industry analysts, which was 355.4 million, according to a company poll.
“The development was held back by the non-renewal of a large contract with a single US customer and temporary operational challenges,” according to a statement released by the company.
When measured in local currency, the company’s sales increased by 1.6%, reaching 1.75 billion francs. However, when the adverse impacts of currency translation were included, sales fell by 5.1%.
